Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction of customary closing conditions. Following the completion of the acquisition, ADx NeuroSciences will become a wholly owned subsidiary of Fujirebio Europe NV.

ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its portfolio of biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.

Fujirebio will combine the know-how and biomarker portfolio of ADx NeuroSciences with both its own experience in bringing IVD products to the market and its strategic CDMO partnerships that make testing solutions available to the diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.

“By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”

“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” stated Koen Dewaele, CEO of ADx NeuroSciences. “Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known.”

Related Links:
Fujirebio 
ADx NeuroSciences